CD274 and neoplasm: Selected biomarkers involving tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death ligand-1 (PD-L1) expression, and tumor-infiltrating lymphocytes have shown early promise in predicting response and benefit from ICIs (14, 18).